Find my Shire Holdings 401(k) plan

Shire Holdings is a global biopharmaceutical company that develops and manufactures treatments for rare diseases, such as Huntington’s disease, attention deficit hyperactivity disorder (ADHD), hemophilia, lysosomal storage disorders (LSDs) and other neurological conditions. Shire was founded in 1986 by Scottish scientist Dr. Angus Russell and American entrepreneur Roy Anderson in Basingstoke, England where it remains headquartered to this day. Although originally focused on the research of rare diseases and treatments, over the years Shire has grown significantly to become one of the world’s leading biotech companies with operations in over 30 countries around the globe. In October 2019, Takeda Pharmaceutical Company Limited acquired Shire providing access to more innovation resources while allowing it to focus on its core strengths in treating rare diseases. With its new parent company Takeda behind it, Shire is now well-positioned to continue developing innovative patient-focused therapies for those struggling with rare diseases worldwide.